Jaguar Animal Health Appoints Karen Wright as Chief Financial Officer
December 16 2015 - 4:05PM
Business Wire
Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the
“Company”), an animal health company focused on developing and
commercializing first-in-class gastrointestinal products for
companion and production animals, and high-value horses, announced
today the appointment of Karen Wright as chief financial officer,
effective immediately. John Kallassy, Jaguar’s former CFO, will
continue to serve the Company as chief operating officer. Mr.
Kallassy will assist with the transition of the CFO role.
Karen Wright brings more than 30 years of financial experience
with a number of international biotech companies. Wright was most
recently head of finance for Clene Nanomedicine. She also served as
vice president of finance and corporate controller at multiple
other private and public companies, including Veracyte (NasdaqGM:
VCYT) and Intermune, which was acquired by Roche. Early in her
career, Wright spent 13 years at Genentech building a strong
foundation in the biotech industry.
“We are excited to welcome Karen to the Jaguar team. With more
than 30 years of senior executive experience in life science
companies, her addition strengthens our leadership team as we look
to expand our clinical and commercial activities,” said Lisa Conte,
Jaguar’s president and CEO. “Karen has proven herself to be a
skilled financial leader by helping multiple companies analyze and
streamline their financial operations, develop new strategies, and
implement new systems, processes and controls needed to scale-up
the businesses.”
“We are very thankful for John’s financial leadership during
Jaguar’s IPO and through our first three quarters as a public
company. He is an integral member of our executive team,” added
Conte.
Karen Wright stated, “I am honored to join such a capable and
experienced management team and become part of a company whose
products are at the forefront of innovation in the animal health
space.”
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused
on developing and commercializing first-in-class gastrointestinal
products for companion and production animals, and high-value
horses. Canalevia™ is Jaguar’s lead prescription drug product
candidate for the treatment of various forms of diarrhea in dogs.
Canalevia™ is a canine-specific formulation of crofelemer, an
active pharmaceutical ingredient isolated and purified from the
Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf
and Neonorm™ Foal are the Company’s lead non-drug products.
Neonorm™ is a standardized botanical extract derived from the
Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products
that act at the same last step in a physiological pathway generally
present in mammals. Jaguar has nine active investigational new
animal drug applications, or INADs, filed with the FDA and intends
to develop species-specific formulations of Neonorm™ in six
additional target species, and formulations of Canalevia™ for cats,
horses and dogs.
For more information, please visit
www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements.” These include statements regarding
the Company’s intention to develop species-specific formulations of
Neonorm™ in additional target species, and the Company’s plan to
develop formulations of Canalevia™ for cats, horses and dogs. In
some cases, you can identify forward-looking statements by terms
such as “may,” “will,” “should,” “expect,” “plan,” “aim,”
“anticipate,” “could,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “potential” or
“continue” or the negative of these terms or other similar
expressions. The forward-looking statements in this release are
only predictions. Jaguar has based these forward-looking statements
largely on its current expectations and projections about future
events. These forward-looking statements speak only as of the date
of this release and are subject to a number of risks, uncertainties
and assumptions, some of which cannot be predicted or quantified
and some of which are beyond Jaguar’s control. Except as required
by applicable law, Jaguar does not plan to publicly update or
revise any forward-looking statements contained herein, whether as
a result of any new information, future events, changed
circumstances or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151216006270/en/
KCSA Strategic CommunicationsGarth Russell,
212-896-1250grussell@kcsa.comAllison Soss,
212-896-1267asoss@kcsa.com
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Apr 2024 to May 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From May 2023 to May 2024